Compounds > ve 821
Page last updated: 2024-11-13

ve 821

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51000408
CHEMBL ID1766779
CHEBI ID124916
SCHEMBL ID2483543
MeSH IDM0560488

Synonyms (51)

Synonym
ve-821 ,
HY-14731
CHEBI:124916
CHEMBL1766779 ,
3-amino-6-(4-(methylsulfonyl)phenyl)-n-phenylpyrazine-2-carboxamide
bdbm50341733
NCGC00346444-01
CS-0238
S8007
1232410-49-9
3-amino-6-(4-methylsulfonylphenyl)-n-phenylpyrazine-2-carboxamide
gtpl8042
ve 821
smr004702977
MLS006011215
DUIHHZKTCSNTGM-UHFFFAOYSA-N ,
SCHEMBL2483543
3-amino-6-[4-(methylsulfonyl)phenyl]-n-phenyl-2-pyrazinecarboxamide
AC-30933
AKOS025212610
ve821
J-690084
3-amino-6-[4-(methanesulfonyl)phenyl]-n-phenylpyrazine-2-carboxamide
DTXSID60679574
mfcd19443686
EX-A530
atr inhibitor iv
HMS3653B19
AS-72494
3-amino-6-(4-(methyl sulfonyl)phenyl)-n-phenyl-2-pyrazinecarboxamide
ve-821, >=98% (hplc)
NCGC00346444-07
3-amino-6-(4-methanesulfonylphenyl)-n-phenylpyrazine-2-carboxamide
SW219507-1
FT-0700135
Q27089128
BCP02617
3-amino-6-(4-(methylsulfonyl)phenyl)-n-phenyl-2-pyrazinecarboxamide
3-azanyl-6-(4-methylsulfonylphenyl)-n-phenyl-pyrazine-2-carboxamide
unii-bf884tq935
2-pyrazinecarboxamide, 3-amino-6-(4-(methylsulfonyl)phenyl)-n-phenyl-
bf884tq935 ,
SB19277
3-amino-6-[4-(methlsulfonyl)phenyl)-n-phenyl-2-pyrazinecarboxamide
HMS3673C07
2-pyrazinecarboxamide, 3-amino-6-[4-(methylsulfonyl)phenyl]-n-phenyl-
HMS3744G05
CCG-268268
nsc-761070
nsc761070
BV168070

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency9.30050.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency9.29110.001310.157742.8575AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency11.98770.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency9.97230.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki50.00000.00021.10439.9000AID1425990
Carbonic anhydrase 1Homo sapiens (human)Ki50.00000.00001.372610.0000AID1425987
Carbonic anhydrase 2Homo sapiens (human)Ki50.00000.00000.72369.9200AID1425988
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)2.21300.00051.350010.0000AID593233; AID705449
Serine-protein kinase ATMHomo sapiens (human)IC50 (µMol)8.00000.00200.29173.4200AID593232
Serine/threonine-protein kinase ATRHomo sapiens (human)IC50 (µMol)0.02600.00301.29487.3000AID593187
Carbonic anhydrase 9Homo sapiens (human)Ki50.00000.00010.78749.9000AID1425989
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (176)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of telomerase activitySerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
pexophagySerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via homologous recombinationSerine-protein kinase ATMHomo sapiens (human)
DNA double-strand break processingSerine-protein kinase ATMHomo sapiens (human)
ovarian follicle developmentSerine-protein kinase ATMHomo sapiens (human)
response to hypoxiaSerine-protein kinase ATMHomo sapiens (human)
somitogenesisSerine-protein kinase ATMHomo sapiens (human)
pre-B cell allelic exclusionSerine-protein kinase ATMHomo sapiens (human)
double-strand break repairSerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via nonhomologous end joiningSerine-protein kinase ATMHomo sapiens (human)
chromatin remodelingSerine-protein kinase ATMHomo sapiens (human)
protein phosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine-protein kinase ATMHomo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
reciprocal meiotic recombinationSerine-protein kinase ATMHomo sapiens (human)
male meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
female meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
signal transductionSerine-protein kinase ATMHomo sapiens (human)
brain developmentSerine-protein kinase ATMHomo sapiens (human)
heart developmentSerine-protein kinase ATMHomo sapiens (human)
determination of adult lifespanSerine-protein kinase ATMHomo sapiens (human)
post-embryonic developmentSerine-protein kinase ATMHomo sapiens (human)
response to ionizing radiationSerine-protein kinase ATMHomo sapiens (human)
regulation of autophagySerine-protein kinase ATMHomo sapiens (human)
positive regulation of gene expressionSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine phosphorylationSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell migrationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of B cell proliferationSerine-protein kinase ATMHomo sapiens (human)
regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
V(D)J recombinationSerine-protein kinase ATMHomo sapiens (human)
cellular response to reactive oxygen speciesSerine-protein kinase ATMHomo sapiens (human)
multicellular organism growthSerine-protein kinase ATMHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSerine-protein kinase ATMHomo sapiens (human)
lipoprotein catabolic processSerine-protein kinase ATMHomo sapiens (human)
signal transduction in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
meiotic telomere clusteringSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell adhesionSerine-protein kinase ATMHomo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine-protein kinase ATMHomo sapiens (human)
protein autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
thymus developmentSerine-protein kinase ATMHomo sapiens (human)
oocyte developmentSerine-protein kinase ATMHomo sapiens (human)
neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
regulation of cell cycleSerine-protein kinase ATMHomo sapiens (human)
histone mRNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
cellular response to retinoic acidSerine-protein kinase ATMHomo sapiens (human)
cellular response to gamma radiationSerine-protein kinase ATMHomo sapiens (human)
cellular response to X-raySerine-protein kinase ATMHomo sapiens (human)
cellular response to nitrosative stressSerine-protein kinase ATMHomo sapiens (human)
cellular senescenceSerine-protein kinase ATMHomo sapiens (human)
replicative senescenceSerine-protein kinase ATMHomo sapiens (human)
establishment of RNA localization to telomereSerine-protein kinase ATMHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine-protein kinase ATMHomo sapiens (human)
regulation of cellular response to heatSerine-protein kinase ATMHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
regulation of microglial cell activationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of TORC1 signalingSerine-protein kinase ATMHomo sapiens (human)
negative regulation of telomere cappingSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomere lengtheningSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine-protein kinase ATMHomo sapiens (human)
regulation of autophagosome assemblySerine-protein kinase ATMHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
telomere maintenanceSerine-protein kinase ATMHomo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleobase-containing compound metabolic processSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase ATRHomo sapiens (human)
negative regulation of DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
response to mechanical stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
replication fork processingSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to UVSerine/threonine-protein kinase ATRHomo sapiens (human)
interstrand cross-link repairSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine/threonine-protein kinase ATRHomo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase ATRHomo sapiens (human)
response to arsenic-containing substanceSerine/threonine-protein kinase ATRHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
protein localization to chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase ATRHomo sapiens (human)
replicative senescenceSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of RNA localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA repairSerine/threonine-protein kinase ATRHomo sapiens (human)
telomere maintenanceSerine/threonine-protein kinase ATRHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine/threonine kinase activitySerine-protein kinase ATMHomo sapiens (human)
DNA-dependent protein kinase activitySerine-protein kinase ATMHomo sapiens (human)
protein bindingSerine-protein kinase ATMHomo sapiens (human)
ATP bindingSerine-protein kinase ATMHomo sapiens (human)
1-phosphatidylinositol-3-kinase activitySerine-protein kinase ATMHomo sapiens (human)
histone H2AXS139 kinase activitySerine-protein kinase ATMHomo sapiens (human)
identical protein bindingSerine-protein kinase ATMHomo sapiens (human)
protein-containing complex bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine kinase activitySerine-protein kinase ATMHomo sapiens (human)
DNA bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutLalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutSalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
histone H2AXS139 kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromosome, telomeric regionSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
site of double-strand breakSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
nucleoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleolusSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
centrosomeSerine-protein kinase ATMHomo sapiens (human)
spindleSerine-protein kinase ATMHomo sapiens (human)
cytosolSerine-protein kinase ATMHomo sapiens (human)
cytoplasmic vesicleSerine-protein kinase ATMHomo sapiens (human)
intracellular membrane-bounded organelleSerine-protein kinase ATMHomo sapiens (human)
DNA repair complexSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase ATRHomo sapiens (human)
site of DNA damageSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase ATRHomo sapiens (human)
PML bodySerine/threonine-protein kinase ATRHomo sapiens (human)
ATR-ATRIP complexSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (109)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1466915Inhibition of ATR in human Ramos cells assessed as reduction in Chk-2 phosphorylation level at 10 uM after 48 hrs by Western blot analysis2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1862499Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 15 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID593232Inhibition of full length recombinant ATM after 24 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID1862502Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303669Cytotoxicity against human K562 cells assessed as decrease in cell viability up to 10 uM after 24 to 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303649Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303656Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID705449Inhibition of DNA-PK2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
AID593187Inhibition of full length recombinant ATR after 24 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID1862486Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303668Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862501Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 15 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303674Potentiation of 500 pM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as decrease in cell viability at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303667Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1466916Induction of apoptosis in human Ramos cells assessed as increase PARP-1 cleavage at 10 uM after 48 hrs by Western blot analysis2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1426010Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 1 hr followed by 4 Gy irradiation under anoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1425989Binding affinity to recombinant human carbonic anhydrase 9 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1862493Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 10 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303652Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862496Antiproliferative activity against human SAOS-2 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303680Induction of apoptosis in human K562 cells assessed as gammaH2AX/53BP1 levels at 10 uM after 48 hrs by DAPI staining based immunofluorescence microscopy2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303653Potentiation of 0.25 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303691Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303659Potentiation of 0.25 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1426008Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 1 hr followed by 2 Gy irradiation under normoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1862500Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303672Potentiation of 50 pM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as decrease in cell viability at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1466977Inhibition of ATR in human U2OS cells assessed as reduction in hydroxyurea-induced Chk-1 phosphorylation at Ser345 residue by measuring ratio of GAPDH level to phosphorylated Chk-1 level at 10 uM preincubated for 1 hr followed by hydroxyurea challenge mea2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1426009Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability at 500 nM pretreated for 1 hr followed by 4 Gy irradiation under anoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1555197Potentiation of cisplatin-induced antiproliferative activity against human HCT116 cells assessed as reduction in cell viability at 500 nM measured after 96 hrs by MTS assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR
AID1862489Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 2 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1426015Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability at 500 nM pretreated for 72 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1303678Induction of apoptosis in human K562 cells assessed as gammaH2AX/53BP1 levels at 10 uM after 48 hrs by DAPI staining based immunofluorescence microscopy in presence of 25 to 250 pM (-)-lomaiviticin A2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303676Induction of DNA double-strand breaks in human K562 cells after 24 hrs by neutral comet assay in presence of (-)-lomaiviticin A2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303660Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862497Antiproliferative activity against human SAOS-2 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 15 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1862494Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303650Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1466976Inhibition of ATR in human U2OS cells assessed as reduction in hydroxyurea-induced Chk-1 phosphorylation at Ser345 residue by measuring ratio of GAPDH level to phosphorylated Chk-1 level at 3 uM preincubated for 1 hr followed by hydroxyurea challenge meas2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1862488Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303654Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303677Induction of DNA double-strand breaks in human K562 cells assessed as median tail moment at 10 uM after 24 hrs by neutral comet assay in presence of 500 pM (-)-lomaiviticin A2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1426018Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM after 72 hrs under anoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1425990Binding affinity to recombinant human carbonic anhydrase 12 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1303657Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1425988Binding affinity to recombinant human carbonic anhydrase 2 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1425987Binding affinity to recombinant human carbonic anhydrase 1 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1862498Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1466911Inhibition of ATR in human U2OS cells assessed as reduction in etoposide-induced Chk-1 phosphorylation at Ser345 residue at 10 uM preincubated for 1 hr followed by etoposide challenge measured after 20 mins by Western blot analysis2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1303664Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1426016Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 72 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1426017Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability at 500 nM after 72 hrs under anoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1862491Antiproliferative activity against human A2780 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 2 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1862521Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 15 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303687Cytotoxicity against human K562 cells assessed as decrease in cell viability up to 2.5 to 10 uM after 24 to 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303645Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862492Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303651Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303666Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303648Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303690Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862487Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 2 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303665Potentiation of 0.25 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862490Antiproliferative activity against human A2780 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID1303647Potentiation of 0.25 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303646Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303663Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303661Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303673Potentiation of 50 pM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as decrease in cell viability at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303658Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1466914Inhibition of ATM in human U2OS cells assessed as reduction in hydroxyurea-induced H2AX phosphorylation at Ser139 residue at 3 to 10 uM preincubated for 1 hr followed by hydroxyurea challenge measured after 2 hrs by Western blot analysis2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1303662Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 10 uM after 48 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1303655Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 24 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1862495Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation at 10 uM incubated for 48 hrs in presence of 15 uM of CDDP by WST-1 assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 2407-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties.
AID593233Inhibition of DNAPK after 2 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID1466910Inhibition of ATM in human U2OS cells assessed as reduction in etoposide-induced Chk-2 phosphorylation at Thr68 residue at 10 uM preincubated for 1 hr followed by etoposide challenge measured after 20 mins by Western blot analysis2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Sulfoximines as ATR inhibitors: Analogs of VE-821.
AID1345671Human ATR serine/threonine kinase (ATR subfamily)2011Nature chemical biology, Apr-13, Volume: 7, Issue:7
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's35 (71.43)24.3611
2020's14 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.29 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index38.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (95.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.1110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
vanillin
Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).		3.1710benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.1510monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
caffeine
[no description available]		2.0610purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		2.1510aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		3.1710chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.1310dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide
[no description available]		2.1510imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
trifluoperazine
[no description available]		3.1710N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.1310L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
quinuclidines
Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.		2.1310quinuclidines;
saturated organic heterobicyclic parent
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.5320mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.1510biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.6820isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		7.49340diazine;
pyrazines		Daphnia magna metabolite
deoxycytidine
[no description available]		3.420pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cladribine
[no description available]		2.2110organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.0110delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
vx
VX nerve agent : A organic thiophosphate that is the ethyl ester of S-{2-[di(propan-2-yl)amino]ethyl} O hydrogen methylphosphonothioate. A toxic nerve agent used in chemical warfare.		3.0110organic thiophosphate;
tertiary amino compound		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neurotoxin
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		3.8820pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		3.420organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		3.0110carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.2110adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
formamidine
formamidine: RN given refers to parent compound. formamidine : The smallest member of the class of carboxamidines being formic acid with the O and OH groups from the carboxy function replaced by NH and NH2 groups respectively. The parent of the class of formamidines.		2.2110carboxamidine;
formamidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
4,5-dimethoxy-2-nitrobenzaldehyde
[no description available]		3.1710aromatic ether;
C-nitro compound
schizandrin b
schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant		3.5720
wortmannin
[no description available]		3.1710acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
nu 6027
[no description available]		3.1710
ku 55933
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source		4.7480
ic 86621
1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone: a DNA-dependent protein kinase inhibitor		3.1710aromatic ketone
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		2.0610organic heterotricyclic compound;
organooxygen compound
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		3.620dibenzothiophenes
veliparib
[no description available]		310benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648
[no description available]		3.1710dibenzothiophenes
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.1310imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
gsk 461364
GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1		2.1510(trifluoromethyl)benzenes
mk-8776
MK-8776: a checkpoint kinase 1 (CHK1) inhibitor; SCH900776 was renamed MK-8776; structure in first source		310pyrazolopyrimidine
olaparib
[no description available]		2.5720cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
v158411
V158411: a Chk1 inhibitor; structure in first source		2.1310
vx-970
berzosertib: an ATR kinase inhibitor		4.1940sulfonamide
chir-124
[no description available]		2.1310
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.1510aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
bmn 673
talazoparib: inhibits both PARP1 and PARP2; structure in first source		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		04.230
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.230
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Acute Lymphoid Leukemia
[description not available]		02.610
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.610
Breast Cancer
[description not available]		02.9130
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9130
Adenocarcinoma, Basal Cell
[description not available]		02.2110
Cancer of Lung
[description not available]		02.2110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.2110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2110
Leukemia, Acute Monocytic
[description not available]		02.2110
Leukemia, Monocytic, Acute
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.		02.2110
Cancer of Pancreas
[description not available]		02.5320
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.5320
Cholangiocellular Carcinoma
[description not available]		02.3110
Ataxia Telangiectasia Syndrome
[description not available]		02.5420
Bile Duct Cancer
[description not available]		02.3110
Ataxia Telangiectasia
An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).		02.5420
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.		02.3110
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.		02.3110
Bone Cancer
[description not available]		02.3110
Osteogenic Sarcoma
[description not available]		02.5820
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.3110
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.5820
Fowl Paralysis
[description not available]		02.2110
Cancer of Ovary
[description not available]		03.4120
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		03.4120
Acute Promyelocytic Leukemia
[description not available]		02.0810
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		02.0810
Glial Cell Tumors
[description not available]		02.1110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.1110
Disease Exacerbation
[description not available]		02.1110
Chromosomal Instability
An increased tendency to acquire CHROMOSOME ABERRATIONS when various processes involved in chromosome replication, repair, or segregation are dysfunctional.		02.1110
Kahler Disease
[description not available]		02.1110
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		02.1110
Local Neoplasm Recurrence
[description not available]		02.1310
Benign Neoplasms, Brain
[description not available]		02.5320
Astrocytoma, Grade IV
[description not available]		02.1110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.5320
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.1110
Cutaneous T-Cell Lymphoma
[description not available]		02.1310
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		02.1310
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.1510